NCT04963595
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Chemotherapy
Key Eligibility Criteria:
Gender: Female
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients without prior treatment that includes both a taxane & Herceptin/trastuzumab, alone or in combination with another agent in the metastatic setting; Patients with a history of HER2 targeting tyrosine kinase inhibitors (e.g. Tukysa/tucatinib, Nerlynx/neratinib, Tykerb/lapatinib); Patients with brain metastases that are untreated, symptomatic, or require therapy to control symptoms
https://ClinicalTrials.gov/show/NCT04963595